BGBC016 STK11 NSCLC (Non-Small Cell Lung Cancer)

We are doing this study to find out if an investigational drug called bemcentinib (the study drug) is a safe and effective option when it is combined with the standard therapy for non-small cell lung cancer (1 immunotherapy drug and 2 chemotherapy drugs).

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Adults ages 18+ who are diagnosed with advanced non-squamous non-small cell lung cancer.

For more information about who can be in this study, please contact the study team at annmarie.peters@duke.edu.

If you join this study, you will go through a screening period to make sure you are eligible. During the screening period you will:

• Have blood draws
• Have imaging scans (CT and MRI)
• Have 2 procedures to check your heart function, an electrocardiogram (ECG) and either an echocardiogram (ECHO) or a multigated acquisition scan (MUGA)

If you are eligible to get the study drug, you will:

• Take the study drug by month once per day
• Received the standard therapy (1 immunotherapy drug and 2 chemotherapy drugs) every 21 days by injection into a vein (IV)